Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.47 |
| ▸ | HRH2 | P25021 | 3/20 | 0.47 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694814 | 1.00 | P2RX7 (0.59) | P2RX7KMT2AADORA1MAPK1P2RY12 | |
| SCHEMBL693690 | 0.91 | P2RX7 (0.57) | P2RX7KMT2AMAPK1P2RY12HRH2 | |
| SCHEMBL719186 | 0.91 | P2RX7 (0.57) | P2RX7KMT2AMAPK1P2RY12HRH2 | |
| SCHEMBL2586086 | 0.89 | LMNA (0.52) | P2RX7KMT2AADORA1MAPK1P2RY12 | |
| SCHEMBL2586090 | 0.89 | LMNA (0.52) | P2RX7KMT2AADORA1MAPK1P2RY12 | |
| SCHEMBL4419865 | 0.88 | P2RX7 (0.54) | P2RX7KMT2AMAPK1HRH2HRH1 | |
| SCHEMBL15083273 | 0.87 | P2RX7 (0.54) | P2RX7KMT2AMAPK1HRH2HRH1 | |
| SCHEMBL2581610 | 0.87 | P2RX7 (0.61) | P2RX7KMT2AADORA1MAPK1HRH2 | |
| SCHEMBL2581609 | 0.87 | P2RX7 (0.61) | P2RX7KMT2AADORA1MAPK1HRH2 | |
| SCHEMBL694636 | 0.85 | P2RY12 (0.51) | P2RX7KMT2AADORA1MAPK1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664203-B2 | Thiazole derivatives and their use as P2Y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-04 | — | — | US | disclosed |
| US-20130281406-A2 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20120053149-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-01 | — | — | US | disclosed |
| EP-2421859-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122504-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053149-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY1, P2RY2 | P2RX7 15/4885KMT2A 4519/4885ADORA1 50/4885 |
| US-20130281406-A2 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY1, P2RY2 | P2RX7 15/4885KMT2A 4528/4885ADORA1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.